{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/osteoporosis-prevention-of-fragility-fractures/management/assessment/","result":{"pageContext":{"chapter":{"id":"bf661812-0f6f-57a2-b0ab-530b799fc4c4","slug":"assessment","fullItemName":"Scenario: Assessment","depth":2,"htmlHeader":"<!-- begin field ed254b7a-f3ac-4c01-a9ee-ea57761a335a --><h2>Scenario: Assessment</h2><!-- end field ed254b7a-f3ac-4c01-a9ee-ea57761a335a -->","summary":"Covers the assessment of fragility fracture risk in primary care.","htmlStringContent":"<!-- begin item 724faa24-2693-4202-ae18-6058fac2c81c --><!-- begin field 1852c974-d916-45d8-a516-acbd0087f6db --><p>From age 18 years onwards.</p><!-- end field 1852c974-d916-45d8-a516-acbd0087f6db --><!-- end item 724faa24-2693-4202-ae18-6058fac2c81c -->","topic":{"id":"9f86812a-068c-512b-a1a4-07fda4301d21","topicId":"a4e2c95c-bf7f-4277-b693-c3b2761380ed","topicName":"Osteoporosis - prevention of fragility fractures","slug":"osteoporosis-prevention-of-fragility-fractures","lastRevised":"Last revised in May 2020","chapters":[{"id":"f651cf3f-ec13-5c52-9121-2dd61c54dc3c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"55fa9b49-e88f-5e9b-8156-01352a4c94b5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a36d9df6-8dba-581c-9361-7b771a120859","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0562cda5-80f8-5d79-83f3-f1233a8060e3","slug":"changes","fullItemName":"Changes"},{"id":"8adeb7b7-191a-5ba3-96f4-d25461c0b901","slug":"update","fullItemName":"Update"}]},{"id":"753ec6fc-9992-587b-870c-2a54cddd30c8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"62fbf7e5-b097-5a47-af2f-56553c8b16fb","slug":"goals","fullItemName":"Goals"},{"id":"e2d42919-7f54-594f-bcb8-06f2625a550f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"eca5799e-0969-539e-b27e-e8ed22c5cc54","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"355020b6-9455-5e78-8a1a-172fc947a117","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3c308a4e-8074-5dca-a9bd-a56405a0595f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"745ec600-96ff-5056-8ab4-7ebb02e5286d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4541ac61-d9f8-5c7e-a415-a2f3b57c3f45","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"36908082-d612-5f9e-8dd3-09d9bc87bf79","slug":"definition","fullItemName":"Definition"},{"id":"127d59dc-ce73-51b5-80c0-d57209058280","slug":"causes","fullItemName":"Causes"},{"id":"4349db35-6c86-5ebc-a13f-6a1dce22e466","slug":"complications","fullItemName":"Complications"},{"id":"710ee28b-5971-5b43-ac4e-22ac6fba154d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c62b535b-c8d0-5ce1-93bb-867c8644eb2f","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"35af4f9e-0536-527c-8b94-94cd5f1fa796","fullItemName":"Management","slug":"management","subChapters":[{"id":"bf661812-0f6f-57a2-b0ab-530b799fc4c4","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"85598d9c-79e5-5925-8dee-46b4cd8f2170","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"f0656a98-39c4-59de-aebb-3eebb0d8dc40","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"38706564-322f-50d2-a7e2-7fe637b76407","slug":"calcium-colecalciferol-vitamin-d3-preparations","fullItemName":"Calcium and colecalciferol (vitamin D3) preparations"},{"id":"0d9951b1-3165-5af5-9601-e12d45a17a6c","slug":"bisphosphonates","fullItemName":"Bisphosphonates"}]},{"id":"c086cbd6-b967-579e-9768-901abfa8d3ca","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"726389ef-f472-5512-a1bf-bf15159602fd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f476f450-a081-5a31-a23e-7b837233a18e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"393e0faf-da4e-5bd5-b705-179c32a6c50b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b11023db-83b9-5207-b99c-7917bef26190","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0b683807-10ff-54fc-936a-06d71aa6f8d4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb240203-2f82-5b14-85ec-55933467aceb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"782a2ad0-e9ec-5fc2-b2e1-95ec79f6a2f8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"35af4f9e-0536-527c-8b94-94cd5f1fa796","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"e914a3ef-12d2-5392-a772-459a5fafa45a","slug":"who-to-assess","fullItemName":"Who to assess","depth":3,"htmlHeader":"<!-- begin field 98541293-9a40-4b85-9aa6-a633c365ef2a --><h3>Who should I assess for fragility fracture risk?</h3><!-- end field 98541293-9a40-4b85-9aa6-a633c365ef2a -->","summary":null,"htmlStringContent":"<!-- begin item e4acf79e-bced-4c3a-8cc4-9eef41db8251 --><!-- begin field 755eba65-6ecb-47ca-8796-cb630949d300 --><p>Identify high-risk groups of people to assess fragility fracture risk. These groups should include:</p><ul><li><strong>All women aged 65 years and over, and all men aged 75 years and over.</strong></li><li><strong>All women aged 50–64 years and all men aged 50–74 years who have any of the following risk factors: </strong><ul><li>A previous osteoporotic fragility fracture.</li><li>Current use or frequent recent use of oral corticosteroids.</li><li>History of falls.</li><li>Low body mass index (less than 18.5 kg/m<sup>2</sup>).</li><li>Smoker.</li><li>Alcohol intake of more than 14 units per week.</li><li>A secondary cause of osteoporosis, including:<ul><li>Hypogonadism in either sex, including untreated premature menopause (menopause before 40 years of age), treatment with aromatase inhibitors (such as exemastane) or gonadotrophin-releasing hormone agonists (such as goserelin).</li><li>Endocrine conditions, including diabetes mellitus, Cushing's disease, hyperthyroidism, hyperparathyroidism, and hyperprolactinaemia.</li><li>Conditions associated with malabsorption including inflammatory bowel disease, coeliac disease, and chronic pancreatitis.</li><li>Rheumatoid arthritis and other inflammatory arthropathies.</li><li>Haematological conditions such as multiple myeloma and haemoglobinopathies.</li><li>Chronic obstructive pulmonary disease.</li><li>Chronic liver failure.</li><li>Chronic kidney disease.</li><li>Immobility.</li></ul></li></ul></li><li><strong>People</strong><strong> younger than 50 years of age with any of the following risk factors:</strong><ul><li>Current or frequent use of oral corticosteroids.</li><li>Untreated premature menopause.</li><li>A previous fragility fracture.</li></ul></li><li><strong>People</strong><strong> younger than 40 years of age with any of the following risk factors:</strong><ul><li>Current or recent use of high-dose oral corticosteroids equivalent to, or more than, 7.5 mg prednisolone daily for 3 months or more.</li><li>Previous fragility fracture of the spine, hip, forearm, or proximal humerus.</li><li>History of multiple fragility fractures.</li></ul></li></ul><p><strong>Consider assessing fracture risk for people taking the following medication, especially in the presence of other <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/background-information/risk-factors/\">Risk factors</a>:</strong></p><ul><li>Selective serotonin reuptake inhibitors. </li><li>Antiepileptic medication — particularly enzyme-inducing drugs, such as carbamazepine. </li><li>Aromatase inhibitors, such as exemastane.</li><li>Gonadotropin-releasing hormone agonists, such as goserelin. </li><li>Proton pump inhibitors. </li><li>Thiazolidinediones, such as pioglitazone.</li></ul><!-- end field 755eba65-6ecb-47ca-8796-cb630949d300 --><!-- end item e4acf79e-bced-4c3a-8cc4-9eef41db8251 -->","subChapters":[{"id":"04b1bc52-07d5-57fa-8d75-47794de792bd","slug":"basis-for-recommendation-0e9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0e2ea7cf-2dfe-4a39-9055-a4219b7d0066 --><h4>Basis for recommendation</h4><!-- end field 0e2ea7cf-2dfe-4a39-9055-a4219b7d0066 -->","summary":null,"htmlStringContent":"<!-- begin item 0e962873-1bc5-41cf-9a60-fafb1bdb9099 --><!-- begin field 96bf1b5a-f960-41dd-9208-5fc8c1c82a2c --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Osteoporosis: assessing the risk of fragility fracture </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>], the National Osteoporosis Guideline Group (NOGG) guideline <em>Osteoporosis: clinical guideline for prevention and treatment </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NOGG, 2016</a>], and the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of osteoporosis and the prevention of fragility fractures </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</p><ul><li>The NOGG guidelines recommend treatment without assessment for [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NOGG, 2016</a>]:<ul><li>Women who have had a previous fragility fracture.</li><li>People over 70 years of age who are taking high dose corticosteroids.</li></ul></li><li>However, both the NICE and SIGN guidelines recommend assessment of all people with risk factors for fragility fracture, except people with hip or vertebral fracture where it is considered inappropriate or impractical [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</li></ul><!-- end field 96bf1b5a-f960-41dd-9208-5fc8c1c82a2c --><!-- end item 0e962873-1bc5-41cf-9a60-fafb1bdb9099 -->","subChapters":[]}]},{"id":"12131b4e-5365-54b3-bdf7-958b392d3364","slug":"how-to-assess","fullItemName":"How to assess","depth":3,"htmlHeader":"<!-- begin field 463fe7a0-cca9-45c0-af31-a0372b16316d --><h3>How should I assess a person for fragility fracture risk?</h3><!-- end field 463fe7a0-cca9-45c0-af31-a0372b16316d -->","summary":null,"htmlStringContent":"<!-- begin item 090de6de-2088-4085-8340-e7307f457fc5 --><!-- begin field b25c22ac-b14e-4993-a71a-a9d09534112d --><ul><li><strong>Exclude non-osteoporotic causes for fragility fractures</strong>.</li><li><strong>Offer </strong><strong>a dual-energy X-ray absorptiometry (DXA) scan</strong> to measure bone mineral density (BMD) <em>without</em> calculating the fragility fracture risk in people:<ul><li>Over 50 years of age with a history of fragility fracture.</li><li>Younger than 40 years of age who have a major risk factor for fragility fracture (see the section <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/background-information/risk-factors/\">What are the risk factors?</a>) — depending on the BMD T-score (see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/background-information/definition/\">What are osteoporosis and osteoporotic fractures?</a>), refer to a specialist experienced in the treatment of osteoporosis.</li></ul></li><li><strong>Consider starting drug treatment in people</strong> with vertebral or hip fractures <em>without </em>undertaking DXA if this is considered inappropriate or impractical (see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/management/#drug-treatment\">Drug treatments</a>).</li><li><strong>For all other people with risk factors for osteoporosis</strong>, calculate the 10-year fragility fracture risk <em>prior</em> to arranging a DXA scan to measure BMD.<ul><li>Consider using the online risk calculators <a style=\"background-color: #ffffff;\" href=\"http://www.qfracture.org/index.php\" data-hyperlink-id=\"ebb79ed6-6486-4aa6-9ee1-a8ff0098fe92\">QFracture®</a> (preferred) or <a style=\"background-color: #ffffff;\" href=\"http://www.shef.ac.uk/FRAX/tool.jsp\" target=\"\" data-hyperlink-id=\"d8000edf-98e1-4090-b87b-a8ff0098ff78\">FRAX®</a>, which predict the absolute risk of hip fracture and major osteoporotic fractures (spine, wrist, hip, or shoulder) over 10 years.</li><li>For information on interpreting the fragility fracture risk score, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/assessment/#interpretation-of-fracture-risk-scores\">How should I interpret a fragility fracture risk score?</a>.<ul><li><strong>Measure</strong> the BMD with DXA (at the spine and hip) in people found to be at high risk of fragility fracture.</li><li><strong>Measure</strong> the BMD with DXA in people whose fracture risk is close to the recommended threshold, who have risk factors that may be underestimated by <a href=\"http://www.shef.ac.uk/FRAX/tool.jsp\" data-hyperlink-id=\"ac35ddf3-8ca1-4635-8314-a8ff0098ffa7\">FRAX®</a>. For more information, see the section <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/assessment/#interpretation-of-fracture-risk-scores\">How should I interpret a fragility fracture risk score?</a></li></ul></li></ul></li><li><strong>Assess </strong><strong>for vitamin D deficiency and inadequate calcium intake</strong>.<ul><li>People are at risk of vitamin D deficiency if they are aged over 65 years, or are not exposed to much sunlight (because they are confined indoors for long periods, or because they wear clothes that cover the whole body).</li><li>A calcium intake of at least 1000 mg/day is recommended for people at increased risk of a fragility fracture. To calculate dietary calcium intake, see the National Osteoporosis Foundation chart <a href=\"https://www.nof.org/patients/treatment/calciumvitamin-d/steps-to-estimate-your-calcium-intake/\" data-hyperlink-id=\"28e8b19e-b9e6-4909-9a25-a8ff0098ffb5\">Steps to estimate your calcium intake</a>.</li></ul></li><li><strong>Identify any</strong> <strong>risk factors for falls</strong><strong>.</strong> For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/falls-risk-assessment/\">Falls - risk assessment</a>.</li></ul><h4>Additional investigations to exclude an underlying cause for fragility fractures and osteoporosis</h4><ul><li><strong>Exclude non-osteoporotic causes of fragility fracture </strong>if there are features of:<ul><li>Metastatic bone disease — bone pain, history of cancer (especially lung, thyroid, prostate, kidney, or breast cancer), or symptoms of undiagnosed cancer (for example unexplained general malaise or weight loss).</li><li>Multiple myeloma — bone pain, anaemia, recurrent infections, bleeding, symptoms of hypercalcaemia, or kidney disease.</li><li>Osteomalacia — bone pain, muscle pain, or proximal muscle weakness.</li><li>Paget's disease — bone pain or deformity.</li></ul></li><li><strong>Exclude secondary causes of osteoporosis</strong> especially in people with a fragility fracture who are at low risk, including men of any age, pre-menopausal women, and women with premature menopause (under 40 years of age). Possible causes include:<ul><li>Endocrine conditions such as untreated premature menopause in women, hypogonadism in men, diabetes mellitus, and hyperthyroidism.</li><li>Rheumatological conditions such as rheumatoid arthritis, and other inflammatory arthropathies.</li><li>Gastrointestinal conditions that cause malabsorption such as Crohn's disease, ulcerative colitis, coeliac disease, and chronic pancreatitis.</li><li>Chronic liver disease.</li><li>Chronic obstructive pulmonary disease.</li></ul></li></ul><!-- end field b25c22ac-b14e-4993-a71a-a9d09534112d --><!-- end item 090de6de-2088-4085-8340-e7307f457fc5 -->","subChapters":[{"id":"2e4181e5-b6ee-521a-a51b-7ef00931dcbd","slug":"basis-for-recommendation-089","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9783b0bf-8dbe-4a6d-b7e6-ac3512ca34e0 --><h4>Basis for recommendation</h4><!-- end field 9783b0bf-8dbe-4a6d-b7e6-ac3512ca34e0 -->","summary":null,"htmlStringContent":"<!-- begin item 089936f0-ef9c-4881-a38f-fa16390982c8 --><!-- begin field 0b32e435-e5b3-4798-93f7-7e444fe10634 --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Osteoporosis: assessing the risk of fragility fracture </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of osteoporosis and the prevention of fragility fractures</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>], and the National Osteoporosis Guideline Group (NOGG) guideline <em>Osteoporosis: clinical guideline for prevention and treatment </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NOGG, 2016</a>]. </p><h5>Excluding other causes of fragility fracture</h5><ul><li>The recommendation to other causes for fragility fracture is based on the expert opinion of the NICE Guideline Development Group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>].</li></ul><h5>People over 50 years of age with a history of fragility fracture</h5><ul><li>The recommendation to offer a dual-energy x-ray absorptiometry (DXA) scan without undertaking a fragility fracture risk assessment in people over 50 years of age with previous history of fragility fractures is based on evidence from a meta-analysis of 11 cohort studies (n = 60,161), which found that previous fragility fracture was associated with an increased risk of any future fracture [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>].</li></ul><h5>People younger than 40 years of age</h5><ul><li>The recommendation to offer a DXA scan to people under 40 years of age and not use <a style=\"background-color: #ffffff;\" href=\"http://www.shef.ac.uk/FRAX/tool.jsp\" data-hyperlink-id=\"b4c42207-64e1-4d11-9b74-a98200dd05f0\">FRAX®</a> or <a style=\"background-color: #ffffff;\" href=\"http://www.qfracture.org/index.php\" data-hyperlink-id=\"69e98d28-b415-46ae-8bce-a98200dd064c\">QFracture®</a> to calculate fragility risk is based on the fact that these risk assessment tools are not applicable in people younger than 40 years of age.<ul><li>DXA scan is recommended in younger people who have had a fragility fracture because they may be at high risk of future fractures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>].</li></ul></li><li>CKS recommends seeking specialist advice on how to manage people younger than 40 years of age following a DXA scan, because there is no evidence or expert opinion available to inform management decisions.</li><li>Be aware that despite having a substantial number of risk factors, the expert opinion of the NICE guideline development group is that the absolute risk of fragility fracture for people younger than 40 may still be low [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>].</li></ul><h5>People with vertebral fractures</h5><ul><li>The recommendation to consider starting drug treatment in people with a vertebral fracture without a DXA scan is based on: <ul><li>The expert opinion of the SIGN guideline development group which considers that the presence of a vertebral fracture signifies the presence of osteoporosis, even if the bone mineral density (BMD) is not within the diagnostic range [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</li><li>Evidence that people with vertebral fractures are at increased future risk of both vertebral and non-vertebral fractures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</li></ul></li></ul><h5>Assessing fragility fracture risk</h5><ul><li>NOGG recommends using <a style=\"background-color: #ffffff;\" href=\"http://www.shef.ac.uk/FRAX/tool.jsp\" data-hyperlink-id=\"0dd1b8cc-1de9-43b3-a854-a98200dd06c0\">FRAX®</a> to assess fracture risk, SIGN recommends <a style=\"background-color: #ffffff;\" href=\"http://www.qfracture.org/index.php\" data-hyperlink-id=\"79cbe1d7-cfea-46e6-9f92-a98200dd0700\">QFracture®</a>, and NICE recommends either method. CKS recommends using <a href=\"http://www.qfracture.org/index.php\" data-hyperlink-id=\"d65544fd-f5c1-42d6-b0f3-a98200dd070e\">QFracture®</a> for calculating fragility fracture risk based on evidence that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>] <a style=\"color: #2a6496; background-color: #ffffff;\" href=\"http://www.qfracture.org/index.php\" data-hyperlink-id=\"2414fb03-b739-4ef0-9a21-a98200dd071b\">QFracture®</a>:<ul><li>Has been extensively validated in the UK and is more accurate than <a href=\"http://www.shef.ac.uk/FRAX/tool.jsp\" target=\"\" data-hyperlink-id=\"6d72e1ef-1370-4a92-a34f-a98200dd0728\">FRAX®</a> at predicting fractures. </li><li>Takes into account many more variables than <a style=\"background-color: #ffffff;\" href=\"http://www.shef.ac.uk/FRAX/tool.jsp\" data-hyperlink-id=\"10061eca-84e3-4d01-86d0-a98200dd075e\">FRAX®</a> (but it does not take into account BMD).</li><li>Has been shown to accurately predict fracture risk in older people up to the age of 85 years.</li></ul></li><li><a style=\"background-color: #ffffff;\" href=\"http://www.qfracture.org/index.php\" data-hyperlink-id=\"9f21b59d-812c-4c5e-8178-a98200dd0790\">QFracture®</a> cannot be recalculated taking BMD measurements into account. However, since the main application of <a style=\"background-color: #ffffff;\" href=\"http://www.qfracture.org/index.php\" data-hyperlink-id=\"8b38b80d-cd9f-4e11-b5d0-a98200dd079e\">QFracture®</a> is to estimate fracture risk prior to carrying out a DXA scan, this may be less important clinically.</li><li><a style=\"background-color: #ffffff;\" href=\"http://www.shef.ac.uk/FRAX/tool.jsp\" data-hyperlink-id=\"51373436-774b-4574-a8eb-a98200dd07ab\">FRAX®</a> underestimates the 10-year fracture risk in people over 75 years of age compared with <a style=\"background-color: #ffffff;\" href=\"http://www.qfracture.org/index.php\" data-hyperlink-id=\"c2798304-bba0-4415-933e-a98200dd07e0\">QFracture®</a>.</li></ul><h5>Arranging a DXA scan</h5><ul><li>The recommendation to measure BMD by DXA at the spine and hip following fracture risk assessment is based on:<ul><li>Evidence that measurement of BMD at the lumbar spine, femoral neck, total hip, and wrist have been shown to predict future fracture occurrence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</li><li>A lack of evidence to support bone-sparing treatment based solely on high fracture risk (without DXA to confirm the presence of osteoporosis) to reduce fracture risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</li></ul></li></ul><h5>Additional investigations</h5><ul><li>The recommendations on additional investigations to consider are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Osteoporosis: assessing the risk of fragility fracture</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>] and the National Osteoporosis Guideline Group (NOGG) guideline <em>Osteoporosis: clinical guideline for prevention and treatment </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NOGG, 2016</a>].</li></ul><!-- end field 0b32e435-e5b3-4798-93f7-7e444fe10634 --><!-- end item 089936f0-ef9c-4881-a38f-fa16390982c8 -->","subChapters":[]}]},{"id":"4cb3f7f4-8c38-557d-b61e-538fed0dc400","slug":"interpretation-of-fracture-risk-scores","fullItemName":"Interpretation of fracture risk scores","depth":3,"htmlHeader":"<!-- begin field 11d69a27-3c6f-4891-a6d0-142935c3dc51 --><h3>How should I interpret a fragility fracture risk score?</h3><!-- end field 11d69a27-3c6f-4891-a6d0-142935c3dc51 -->","summary":null,"htmlStringContent":"<!-- begin item bd6329db-c534-4c4e-8f8a-3484702af78d --><!-- begin field a4c8d4e6-77d5-40a4-a267-8a87892b3004 --><p>The <a href=\"http://www.qfracture.org/index.php\" data-hyperlink-id=\"77881d02-25c3-4d2e-811a-a98200dd3339\">QFracture®</a> and <a href=\"http://www.shef.ac.uk/FRAX/tool.jsp\" data-hyperlink-id=\"de4d3530-c205-42b1-a8a8-a98200dd3346\">FRAX® </a>risk assessment tools predict the absolute risk of hip fracture, and major osteoporotic fractures (spine, wrist, or shoulder) over 10 years.</p><ul><li>A 10-year fracture risk of 10% is considered to be the threshold for arranging a dual-energy X-ray absorptiometry (DXA) scan in men and women. However, a pragmatic approach is advised and clinical judgement and local pathways should be considered. <ul><li>When using the <a href=\"http://www.qfracture.org/index.php\" data-hyperlink-id=\"34f85f6e-dd30-460e-9f90-a98200dd3382\">QFracture®</a> calculator, be aware that for women the cut off for the top 10% at highest risk is a 10-year risk of 11.1%, and for men the cut off for the top 10% at highest is 2.6%.</li></ul></li><li>When using <a href=\"http://www.shef.ac.uk/FRAX/tool.jsp\" data-hyperlink-id=\"a07b0d43-755c-4356-8503-a98200dd3393\">FRAX®</a>, the fracture risk is calculated and clicking on the 'view NOGG guidance' button shows a chart which plots a person's calculated risk against their age. This graphically represents a person's risk as being at low (green zone), high (red zone), or intermediate (orange zone) risk for an osteoporotic fracture.</li><li>Be aware that <a href=\"http://www.shef.ac.uk/FRAX/tool.jsp\" data-hyperlink-id=\"67d3721b-9b6f-476e-bea4-a98200dd33c7\">FRAX®</a> underestimates some risk factors, including:<ul><li>Regular use of corticosteroids equivalent to or less than 5 mg prednisolone daily.</li><li>Use of corticosteroids more than or equivalent to 7.5 mg prednisolone daily for more than 3 months. </li><li>A history of multiple fragility fractures. </li><li>High alcohol intake.</li><li>Heavy smoking.</li></ul></li><li>In people aged over 80 years of age, interpret the estimated 10-year fracture risk with caution, as the short-term fracture risk may be underestimated. </li></ul><p><strong>Table 1.</strong> How to interpret a fragility fracture risk score</p><table><thead><tr><th scope=\"col\"> </th><th scope=\"col\">QFracture®</th><th scope=\"col\">FRAX®</th></tr></thead><tbody><tr><td>High risk</td><td>Risk score is 10% or greater</td><td>Red zone of risk chart</td></tr><tr><td>Intermediate risk</td><td>Risk score is close to, but below 10%</td><td>Orange zone of risk chart</td></tr><tr><td>Low risk</td><td>Risk score is below 10%</td><td>Green zone of risk chart</td></tr></tbody></table><!-- end field a4c8d4e6-77d5-40a4-a267-8a87892b3004 --><!-- end item bd6329db-c534-4c4e-8f8a-3484702af78d -->","subChapters":[{"id":"5675a39b-fbfa-510a-9c0a-3bd76d40a94f","slug":"basis-for-recommendation-8c7","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3668cb45-3f4d-46c0-b1d0-72cbc8f2fb57 --><h4>Basis for recommendation</h4><!-- end field 3668cb45-3f4d-46c0-b1d0-72cbc8f2fb57 -->","summary":null,"htmlStringContent":"<!-- begin item 8c7d8272-7903-4f75-b51e-bc5130a443a2 --><!-- begin field 971461f3-245f-42e2-a41f-2f826728d18d --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Osteoporosis: assessing the risk of fragility fracture</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>] and the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of osteoporosis and the prevention of fragility fractures</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</p><ul><li>The NICE guideline development group considered it outside the scope of its guideline to recommend intervention thresholds for people being assessed for fragility fracture risk.</li><li>SIGN recommends a fragility fracture risk threshold of 10% to indicate the need for a dual-energy X-ray absorptiometry (DXA) scan for both men and women.</li><li>However, the <a href=\"https://qfracture.org/index.php\" data-hyperlink-id=\"97f155db-5e74-40b3-968b-abb300f3d9eb\">QFracture</a> risk calculator acknowledges that there is no generally agreed threshold regarding the definition of high risk, and provides details on absolute risk and defines thresholds for men and women separately:<ul><li>For women, the cut off for the top 10% at highest risk is a 10-year risk of 11.1%.</li><li>For men, the cut off for the top 10% at highest risk is 2.6%.</li></ul></li><li>The recommendation to treat fracture risk scores in people older than 80 years of age with caution is based on the expert opinion of the NICE guideline development group.</li></ul><!-- end field 971461f3-245f-42e2-a41f-2f826728d18d --><!-- end item 8c7d8272-7903-4f75-b51e-bc5130a443a2 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}